ArticleGut pathogens2025
Synergistic potentiation of antibiotics by chamomile phytochemicals against multidrug-resistant Helicobacter pylori.
Article in Gut pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHelicobacter pylori is a significant global health issue, infecting nearly half of the population. Increasing antibiotic resistance leads to treatment failures. This study examined the antibacterial effects of chamomile ethanolic extract, both alone and combined with standard antibiotics, as a potential approach to fighting antibiotic-resistant H. pylori strains.
methodsThirty antral gastric biopsies were collected from patients undergoing diagnostic upper endoscopy at El-Demerdash Hospital in Cairo, Egypt. H. pylori isolates were identified by rapid urease test (RUT), cultured, and tested for antimicrobial susceptibility to clarithromycin (CLR, 15 µg), metronidazole (MET, 5 µg), amoxicillin (AX, 25 µg), tetracycline (TE, 30 µg), rifampicin (RA, 30 µg), and levofloxacin (LEV, 5 µg). The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were determined. The antibacterial activity of chamomile ethanolic extract was tested alone and in combination with these antibiotics. Phytochemical profiling was conducted using FT-IR and GC-MS. The identified compounds were analyzed through molecular docking against ten H. pylori targets: lipoprotein 20 (LPP20, HP1456), aspartate α-decarboxylase (ADC), S-ribosylhomocysteinase (LuxS), GTP cyclohydrolase II (GCH II), cytotoxin-associated gene A (CagA), sialic acid-binding adhesin (SabA), blood group antigen-binding adhesin (BabA), vacuolating cytotoxin A (VacA), and fructose-1,6-bisphosphate aldolase (FBA), using AutoDock Vina 1.5.7.
resultsAll thirty biopsies tested positive for RUT, although only 20 yielded successful cultures. The chamomile ethanolic extract demonstrated anti-H. pylori activity against all 20 isolates, with MIC values ranging from 1.562 to 6.25 mg/mL and MBC values from 3.12 to 12.5 mg/mL. When combined with antibiotics, the extract altered their antibacterial activity, primarily producing synergistic effects, while a few combinations exhibited antagonistic effects. Notably, in cases where antibiotics alone had limited activity, adding chamomile extract significantly enhanced effectiveness, increasing inhibition zones by 2.2-fold for tetracycline, 2.1-fold for rifampicin, and 1.7-2.3-fold for levofloxacin. FT-IR analysis confirmed the chemical safety of the extract, while GC-MS profiling identified 38 constituents, including 14 compounds with known antimicrobial properties. Molecular docking revealed strong binding affinities of eight bioactive compounds toward H. pylori target proteins. Additionally, Lipinski's Rule of Five and ADMET profiling indicated these compounds possess favorable drug-like properties, including safety and oral bioavailability.
conclusionsChamomile ethanolic extract shows promising anti-H. pylori activity and can enhance the effectiveness of standard antibiotics, indicating its potential as a complementary treatment to combat antibiotic-resistant H. pylori infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.